Skip to content
Review Open access

CD8+ T Cell Exhaustion and Tumor Immune Checkpoint Blockade: Mechanisms, Heterogeneity, and Combination Intervention Strategies

Sep 2026 · Advances in World Medical Research · 0 citations · 24 references

Abstract

CD8+ T cells are the core effector cells in anti-tumor immunity, but under continuous tumor antigen stimulation and inhibitory microenvironment, they gradually enter a state of dysfunction, showing reduced effector secretion, decreased proliferation, persistent expression of inhibitory receptors, and abnormal metabolic adaptation, which are driven by a unified transcriptional, epigenetic, metabolic, and microenvironmental exhaustion program. T cell exhaustion is a major reason why immune checkpoint blockade (ICB) therapy has limited effectiveness and also a key target for combination treatment strategies. In recent years, single-cell sequencing, spatial transcriptomics, and functional immunology studies have shown that exhausted T cells are not a single state-they include heterogeneous subgroups such as progenitor exhausted T cells (Tpex), intermediate exhausted T cells, and terminal exhausted T cells. Blocking PD-1/PD-L1 and CTLA-4 can partly restore T cell function, but primary and secondary resistance are still common. This article reviews the unified mechanisms of CD8+ T cell exhaustion and, organized around the axis of 'mechanism–heterogeneity–ICB response–combination strategies', explores potential strategies for immune checkpoint blockade related to CD8+ T cell exhaustion, and also discusses biomarkers and future research directions.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.